Jagsonpal Pharmaceuticals Approves Grant of 1,93,000 Employee Stock Options
Jagsonpal Pharmaceuticals Limited announced on April 27, 2026, that its Nomination and Remuneration Committee approved the grant of employee stock options. The approval pertains to the company's existing Jagsonpal Pharmaceuticals Limited Employees Stock Option Plan, 2022.The Committee approved the issuance of 1,93,000 employee stock options. These options carry an exercise price of Rs. 159.50 per option.
The granted options are structured to be convertible into an equivalent number of equity shares, each valued at Rs. 2.00.
The options are set to vest through a defined schedule. The vesting process will occur in 4 equal annual tranches, beginning from the first anniversary of the grant date.
The core details of the employee stock option grant are summarized below:
| Parameter | Detail |
|---|---|
| Approving Body | Nomination and Remuneration Committee of the Board of Directors |
| Date of Approval | April 27, 2026 |
| Plan Name | Jagsonpal Pharmaceuticals Limited Employees Stock Option Plan, 2022 |
| Total Options Granted | 1,93,000 |
| Exercise Price per Option | Rs. 159.50 |
| Conversion Value per Share | Rs. 2.00 |
| Vesting Schedule | 4 equal annual tranches (commencing from the first anniversary) |
JAGSNPHARM Stock Price Movement
Today, shares of Jagsonpal Pharmaceuticals Limited gained 2.23%, settling at ₹203.67 in post-market trading. The stock saw a noticeable uptick, supported by a trading volume of 148,205 shares throughout the day.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.